Merck & Co. Pre-Tax Income decreased by 203.3% to -$3.53B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 159.9%, from $5.90B to -$3.53B. Over 3 years (FY 2021 to FY 2025), Pre-Tax Income shows an upward trend with a 14.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
This provides a view of profitability that is not skewed by varying tax rates or one-time tax credits.
A company's profits before the deduction of corporate income tax. It combines operating performance with non-operating f...
Used to compare companies across different tax jurisdictions to see who generates more raw profit.
income_before_tax| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.72B | $5.27B | $3.43B | $4.86B | $4.49B | $3.58B | $3.51B | $3.65B | -$5.34B | $5.62B | $5.67B | $6.01B | $4.09B | $4.17B | $5.90B | $5.00B | $6.75B | $3.42B | -$3.53B |
| QoQ Change | — | +206.7% | -34.8% | +41.6% | -7.7% | -20.1% | -2.0% | +3.9% | -246.2% | +205.3% | +0.9% | +5.9% | -31.9% | +2.0% | +41.6% | -15.3% | +34.9% | -49.3% | -203.3% |
| YoY Change | — | — | — | — | +161.3% | -32.0% | +2.3% | -24.9% | -218.9% | +56.9% | +55.3% | +212.6% | -27.2% | — | +4.1% | -16.8% | +64.9% | -18.0% | -159.9% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | $11.20B | $11.55B | $10.88B | $10.71B | $11.01B | $12.54B | $11.49B | $11.52B |
| Animal Health | $508.00M | $510.00M | $365.00M | $634.00M | $593.00M | $511.00M | $393.00M | $722.00M |
| Total | $6.01B | $4.09B | $4.17B | $5.90B | $5.00B | $6.75B | $3.42B | -$3.53B |
Animal Health, Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.